Kirkman(R) Unveils Revolutionary L Reuteri: a Brain-Protective Probiotic with Immune Benefits

Rhea-AI Summary

Functional Brands (NASDAQ: MEHA) announced Kirkman® L. Reuteri PLUS on February 2, 2026, a probiotic formulated to support gut health, immune function, and gut‑brain communication during pregnancy. The product is made in a GMP‑certified facility and is free from gluten, dairy, soy, and common allergens. It is available on Kirkman’s website and authorized distributors.

News Market Reaction – MEHA

+2.50%

6 alerts

+2.50% Session close to close

+2.4% Peak Tracked

-14.6% Trough Tracked

$3.54M Market Cap

1.1x Rel. Volume

In the Feb 2 session, MEHA gained 2.50%, reflecting a moderate positive market reaction. Argus tracked a peak move of +2.4% during that session. Argus tracked a trough of -14.6% from its starting point during tracking. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement extends Functional Brands’ Kirkman lineup with a prenatal-focused L. reuteri probi...

Analysis

This announcement extends Functional Brands’ Kirkman lineup with a prenatal-focused L. reuteri probiotic emphasizing gut-brain and immune support. It follows recent launches and transparency milestones, while filings show Q3 2025 revenue of $1,694,174 and net income of $259,001 but also negative working capital of $1,491,727. Investors may weigh new product momentum against the going-concern language in the 10-Q and the company’s history of sizable moves after news.

Key Figures

Q3 2025 net revenue: $1,694,174 Q3 2024 net revenue: $1,395,913 Q3 2025 gross profit: $978,350 +5 more

8 metrics

Q3 2025 net revenue $1,694,174 Quarter ended September 30, 2025

Q3 2024 net revenue $1,395,913 Prior-year quarter comparison

Q3 2025 gross profit $978,350 Quarter ended September 30, 2025

Q3 2025 net income $259,001 Helped by Employee Retention Tax Credit refund

Employee Retention Tax Credit refund $491,801 Recorded in other income in Q3 2025

Nine-month 2025 revenue $5,116,963 Nine months ended September 30, 2025

Negative working capital $1,491,727 As of September 30, 2025

Private placement proceeds $8,000,000 Series A and B preferred stock after quarter-end

Historical Context

5 past events · Latest: Jan 20 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jan 20	Product launch	Positive	+5.0%	Introduced Kirkman Detox Aid bundle targeting detoxification support and liver health.
Dec 22	Product launch	Positive	-6.3%	Launched Skin, Beauty & Anti-Aging bundle for holistic skin and cellular support.
Dec 15	Earnings report	Positive	-28.0%	Reported Q3 2025 revenue growth, margin expansion, and swing to net income.
Dec 08	Investor conference	Neutral	+5.9%	Announced participation in Sidoti virtual investor conference with management presentation.
Dec 02	Product/regulatory	Positive	+3.9%	Highlighted P2i prenatal as first aligned with FIGO transparency and California SB 646.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent MEHA news often triggers meaningful moves, with positive product and quality announcements sometimes aligning with gains but earnings strength previously met with sharp selling.

Recent Company History

Over the last few months, Functional Brands has focused on new Kirkman-branded offerings and transparency initiatives. Launches such as the Detox Aid bundle on Jan 20, 2026 and prior skin and prenatal products have targeted detox, beauty, and prenatal niches, with mixed share-price reactions. The strong Q3 2025 earnings report on Dec 15 showing higher revenue and a swing to profit nevertheless saw a steep selloff, highlighting investor sensitivity despite operational progress. Today’s new prenatal-focused probiotic extends this product-innovation trajectory.

Key Terms

gut-brain communication, microbiome, gut-brain axis, neurotransmitter signaling, +2 more

6 terms

gut-brain communication medical

"formulated to support gut health, immune function, and gut-brain communication during pregnancy"

Gut-brain communication is the two-way signaling between the digestive system — including gut microbes — and the brain, like a biological telephone line where chemical messengers, nerves and immune signals carry information back and forth. Investors care because therapies, drugs and consumer products that target this link (for mood, appetite, digestion or neurological conditions) can open new markets, affect regulatory review paths and change revenue prospects for healthcare and food companies.

microbiome medical

"role of the maternal gut microbiome in immune development, metabolic health"

Microbiome is the community of tiny living organisms—bacteria, viruses, fungi and their genes—that live in a particular place, like the gut, skin or soil; think of it as a neighborhood of microscopic life that affects how that environment works. Investors care because changes or products that target the microbiome can alter health outcomes, crop yields or consumer product performance, creating new markets, regulatory risks and potential shifts in revenue for companies.

gut-brain axis medical

"Potential Benefits of Kirkman4 L. Reuteri PLUSGut-Brain Axis SupportEmerging research suggests"

A two-way communication system connecting the gut and the brain through nerves, chemical signals, immune reactions and the community of microbes living in the gut. Think of it as a phone line where messages about digestion, stress and inflammation are exchanged and can influence mood, behavior and physical health. Investors care because therapies, supplements and diagnostics that target this connection can create new markets, change clinical strategies and affect regulatory and commercial risk.

neurotransmitter signaling medical

"may influence gut-brain communication through immune modulation, neurotransmitter signaling, and vagal nerve"

Neurotransmitter signaling is the process by which nerve cells send messages using chemical messengers called neurotransmitters; one cell releases the chemical into a tiny gap and a neighboring cell detects it, like passing a note across a desk. For investors, it matters because many drugs and medical devices aim to change these chemical messages to treat brain and nervous system disorders, so advances or setbacks in this area can strongly affect product value, regulatory risk, and market potential.

vagal nerve medical

"gut-brain communication through immune modulation, neurotransmitter signaling, and vagal nerve pathways"

The vagal nerve is a major cranial nerve that acts like a body-wide telephone line, carrying signals between the brain and organs such as the heart, lungs and gut to regulate heart rate, digestion and inflammation. It matters to investors because medical devices, drugs or therapies that stimulate or block this nerve can change patient outcomes, drive regulatory reviews, and create commercial opportunities or risks in markets for neurological, cardiac and gastrointestinal treatments.

GMP-certified technical

"Kirkman4 L. Reuteri PLUS is manufactured in its GMP-certified facility"

GMP-certified means a manufacturer has been inspected and approved for following Good Manufacturing Practice rules that ensure products are made consistently, safely, and meet quality standards. Think of it like a professional kitchen that follows strict recipes, cleanliness rules and checks so meals are safe every time. For investors, GMP certification lowers regulatory and product-risk, supports market access and brand trust, and can reduce the chance of costly recalls or production shutdowns.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Lake Oswego, Oregon--(Newsfile Corp. - February 2, 2026) - Functional Brands Inc. (NASDAQ: MEHA), parent company of Kirkman®, a trusted leader in high-quality dietary supplements, today announced the launch of Kirkman® L. Reuteri PLUS, a next-generation probiotic formulated to support gut health, immune function, and gut-brain communication during pregnancy.

Pregnancy represents a critical window for both maternal well-being and fetal development. Growing scientific evidence highlights the important role of the maternal gut microbiome in immune development, metabolic health, and neurological signaling. Lactobacillus Reuteri, a well-studied probiotic species, has been shown in clinical and preclinical research to influence immune responses, digestive balance, and microbiota-brain signaling pathways.

Kirkman® L. Reuteri PLUS was developed to help maintain a balanced gut microbiome, which is increasingly recognized as a foundational component of maternal health and early immune system maturation in infants.

Potential Benefits of Kirkman® L. Reuteri PLUS

• Gut-Brain Axis Support
  Emerging research suggests that certain strains of L. reuteri may influence gut-brain communication through immune modulation, neurotransmitter signaling, and vagal nerve pathways. This interaction may play a role in supporting emotional well-being and cognitive function—areas of heightened importance during pregnancy.

• Immune System Development and Regulation
  L. reuteri has been studied for its ability to support immune system maturation and regulatory balance. Maternal probiotic intake may contribute to immune development in the fetus and infant, potentially supporting healthy immune responses early in life.

• Support for the Body's Natural Defenses
  By helping maintain microbial balance and intestinal barrier function, L. reuteri may support the body's natural defenses against pathogens. This is particularly relevant during pregnancy, when immune function undergoes adaptive changes.

• Digestive Comfort and Gut Health
  Hormonal changes during pregnancy can affect digestion and gut motility. L. reuteri has been shown to support digestive balance and gastrointestinal comfort, contributing to overall maternal wellness.

Quality and Scientific Integrity

Kirkman® L. Reuteri PLUS is manufactured in its GMP-certified facility and formulated to meet Kirkman®'s rigorous quality standards. The product is free from gluten, dairy, soy, and common allergens, making it suitable for individuals with dietary sensitivities.

"We are proud to introduce L. Reuteri PLUS as part of our ongoing commitment to science-driven innovation," said Eric Gripentrog, CEO of Functional Brands Inc. "As research continues to expand our understanding of the microbiome's role in immune and neurological health, this product reflects our focus on delivering thoughtfully formulated supplements designed to support wellness during critical life stages, including pregnancy."

Availability: How to Purchase L Reuteri Plus?

Kirkman® L Reuteri PLUS is now available for purchase on the official Kirkman® website and through authorized distribution partners. For more information about the product, its benefits, and how to order, visit www.kirkmangroup.com.

About Functional Brands Inc. and Kirkman®

Functional Brands Inc., the parent company of Kirkman®, is committed to developing clinically aligned health products that bridge science, practitioner trust, and patient safety. Every product under the Functional Brands umbrella is formulated with a commitment to transparency, testing, and results.

Kirkman® has been the leader in Ultratested® supplements since 1949, setting the gold standard in purity and hypoallergenic formulation. Our rigorous standards ensure that even the most sensitive communities—including those who cannot tolerate other supplements—can thrive from our formulations. With more than 70 years of clean science behind every product, Kirkman® is trusted by practitioners and patients worldwide for developing the cleanest, most precisely tested supplements available.

Informative Scientific Sources Supporting the Stated Benefits

Below are high-quality, peer-reviewed sources commonly cited in scientific and clinical discussions of Lactobacillus reuteri, probiotics, pregnancy, immune development, and the gut-brain axis. These sources support mechanisms, associations, and emerging evidence, not drug-level claims.

Gut-Brain Axis & Brain Health

1. Cryan JF, et al. (2019).
   The microbiota–gut–brain axis. Physiological Reviews.
   → Foundational review explaining how gut microbes influence brain function, mood, and behavior.

2. Sgritta M, et al. (2019).
   Mechanisms underlying microbial-mediated changes in social behavior in mice. Neuron.
   → Demonstrated L. reuteri's role in vagus-nerve-mediated social and neurological signaling (preclinical).

3. Dinan TG & Cryan JF (2017).
   The microbiome-gut-brain axis in health and disease. Gastroenterology Clinics.

Immune Development & Pregnancy

4. Korpela K, et al. (2018).
   Maternal probiotic supplementation during pregnancy impacts infant immune development. Clinical & Experimental Allergy.

5. Rautava S, et al. (2012).
   Probiotics modulate host–microbe interaction in the placenta and fetal gut. Placenta.

6. West CE, et al. (2017).
   Probiotics during pregnancy and infancy and the immune system. Current Opinion in Allergy and Clinical Immunology.

Protection Against Infections / Immune Regulation

7. Spinler JK, et al. (2014).
   Human-derived probiotic Lactobacillus reuteri demonstrates antimicrobial activity. Gut Microbes.

8. Hemarajata P & Versalovic J (2013).
   Effects of probiotics on gut microbiota. Gastroenterology.

Digestive Health

9. Savino F, et al. (2010).
   Lactobacillus reuteri in infantile colic and gastrointestinal function. Pediatrics.

10. Walter J, et al. (2011).
    Ecological dynamics of Lactobacillus reuteri. Environmental Microbiology.

Important Note (for Internal or Legal Review)

• Evidence for probiotics in pregnancy is supportive but not definitive.

• Claims should remain framed as "supports," "may help," or "associated with", not as prevention or treatment of disease.

• Strain specificity matters—clinical substantiation should align with the exact strain(s) used in L. reuteri PLUS.

Investor Relations Contact:
FunctionalBrands@icrinc.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/282326

FAQ

What is Kirkman L. Reuteri PLUS (MEHA) and when was it launched?

Kirkman L. Reuteri PLUS is a pregnancy‑focused probiotic launched February 2, 2026. According to Functional Brands, it targets maternal gut balance, immune support, and gut‑brain communication with a formulation produced in a GMP‑certified facility and carrier‑free of common allergens.

What pregnancy benefits does Kirkman L. Reuteri PLUS (MEHA) claim to provide?

The product claims to support digestive comfort, immune regulation, and gut‑brain signaling during pregnancy. According to Functional Brands, L. reuteri strains in the formula are intended to help maintain microbial balance, intestinal barrier function, and aspects of maternal well‑being.

Is Kirkman L. Reuteri PLUS (MEHA) safe for people with dietary sensitivities?

Kirkman L. Reuteri PLUS is formulated without gluten, dairy, soy, and common allergens to suit dietary sensitivities. According to Functional Brands, the product is made in a GMP‑certified facility and follows Kirkman quality standards for allergen‑free labeling and manufacturing.

Where can investors and customers purchase Kirkman L. Reuteri PLUS (MEHA)?

Kirkman L. Reuteri PLUS is available for purchase on the official Kirkman website and through authorized distribution partners. According to Functional Brands, ordering details, product specifications, and authorized reseller information are posted on www.kirkmangroup.com.

Does Kirkman L. Reuteri PLUS (MEHA) cite clinical research supporting its claims?

The company cites existing clinical and preclinical research on Lactobacillus reuteri and gut‑brain and immune effects. According to Functional Brands, the product is formulated based on that body of research but the announcement does not present new trial results or quantified clinical endpoints.